Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Atomic AI generates the structure data it needs for its AI model with the aim of RNA drug discovery.
The therapeutic principle of allogeneic hematopoietic cell transplantation, one the most common forms of cancer immunotherapy, is alloreactivity, yet its molecular determinants remain largely unknown. An analytical framework now enables personalized assessment of alloreactivity from whole-exome sequencing of donor–recipient pairs, to help with prognostication of disease relapse and immune-mediated complications.
We have discovered an effect, termed stacking-induced intermolecular charge transfer-enhanced Raman scattering (SICTERS), that enhances the Raman signal intensities of small molecules by relying on their self-stacking rather than external substrates. This effect enables the design of substrate-free small-molecule probes for high-resolution, non-invasive transdermal Raman imaging of lymphatic drainage and microvessels.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. A rescued chimeric antigen receptor from Cargo Therapeutics for hard-to-treat lymphomas shows promise in patients while a trispecific advances toward human testing.
Companies are moving therapeutic testing from plastic wells into pooled in vivo screening, generating physiologically relevant data by screening many drug candidates at once in a single animal.
The resurrection of strings of extinct molecules raises intriguing questions of patentability and bioethical considerations in an emerging area of patent law.